TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05179057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as 2-4 milliliter infusion, visually identical to Posoleucel
Study: NCT00085345
Drug: ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06480123
Drug: Skin drug prepared with exome originated from stem cell
Normalized name: human skin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin drug prepared with exome originated from stem cell will be applied to patient with diabetic foot.
Study: NCT05282771
Drug: Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
Study: NCT05282771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
Study: NCT06009198
Drug: Iron folate tablets
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron folate tablets will be administered to the underweight school going adolescents girls and boys to see the affect on BMI and micronutrients
Study: NCT05551910
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the control group were given remifentanil (1mg / branch, Yichang humanwell Pharmaceutical Co., Ltd.) 0.05-2ug/kg Minutes after administration, the analgesic score was measured with cpot pain observation scale. The target cpot was less than 3 points, and the dose of remifentanil was adjusted according to the cpot score.
Study: NCT05357027
Drug: Cyclophosphamide Capsules
Normalized name: Cyclophosphamide Capsules
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Study: NCT06010342
Drug: TL118 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT05427175
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
Study: NCT04800224
Drug: Standardized Brazilian Green Propolis Extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900mg/day of Standardized Brazilian Green Propolis Extract for 10 days.
Study: NCT04800224
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900mg/day of Placebo for 10 days.
Study: NCT04303559
Drug: Eloctate Injectable Product
Normalized name: Eloctate Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a factor VIII-Fc fusion protein.
Study: NCT03720990
Drug: Cholic Acid
Normalized name: Cholic Acid
DrugBank: Cholic Acid (DB02659)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be treated with cholic acid for 8 weeks
Study: NCT06059989
Drug: Immunosuppressive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group only
Study: NCT06087094
Drug: HRS-7450 ；Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-7450 or Placebo
Study: NCT06725355
Drug: IN-R00002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of IN-R00002 60mg
Study: NCT06725355
Drug: IN-G00002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of IN-G00002 60mg
Study: NCT06225882
Drug: Oxaluria evolution.
Approvals — FDA: no, EMA: no, PMDA: no
Description: To collect real data from the specific French experience by collecting data from patients treated throughout the country and to monitor in particular the evolution of oxaluria before and after treatment.
Study: NCT06726278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants will receive a placebo treatment, consisting of an inert substance that has no active pharmacological effect. The placebo is administered in the same manner (vaginally) and at the same time point as Misoprostol, but without any therapeutic action. This group is used to control for potential psychological effects of the intervention, ensuring that any observed
Study: NCT06725641
Drug: Test preparation：Methylcholine chloroacetate for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinergic agonists
Study: NCT06725641
Drug: Reference preparation：Methylcholine chloroacetate for inhalation（Provocholine）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinergic agonists
Study: NCT06040944
Drug: antipsychotic drugs inducing hyperprolactinemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: not exposed
Study: NCT04673578
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective COX-2 inhibitor; nonsteroidal anti-inflammatory drug (NSAID)
Study: NCT06231979
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml normal saline 0.9% per side in erector spinae block
Study: NCT06225999
Drug: LLV (levoisomer form of leucovorin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LLV will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
Study: NCT06345833
Drug: 3% TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% TXA on TXA-soaked pledgets applied for 10 minutes with saline as the control.
Study: NCT06345833
Drug: 1% TXA with local plus 3% TXA-soaked pledgets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% TXA with local plus 3% TXA-soaked pledgets with saline as the control.
Study: NCT06047860
Drug: PD-1/PD-L1 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1/PD-L1 inhibitor within one week of radiotherapy
Study: NCT06489860
Drug: HIV
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directions: For adults and for Children 1-12 years old. Indication: Anti-AIDS Drug. Ingredient: Organic Rice 91% and Honey 9% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours.~Humidification: \<5%. Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time. Use within two years from the manufacturing date.
Study: NCT06489860
Drug: Neoplasms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directions: For adults and for Children 1-12 years old. Indication: Malignant Neoplasms . Ingredient: Rice 90% and Honey 10% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours.~Humidification: \<5%. Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time. Use within two years from the manufacturing date.
Study: NCT04898322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04983745
Drug: Combination drug
Normalized name: combination drugs used in erectile dysfunction
Approvals — FDA: no, EMA: no, PMDA: no
Description: niraparib and dostarlimab combination
Study: NCT06022536
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects injected with Placebo
Study: NCT05545072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo to match dupilumab will be administered subcutaneously every 2 weeks until the end of treatment (EOT) at Week 52. Participants will receive a total of 26 doses.
Study: NCT05545072
Drug: Intranasal Corticosteroid Sprays (INCS)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will undergo standardized background therapy with intranasal corticosteroid sprays (INCS) per standard of care (SoC). This will be continued throughout the entire study. Participants either receive fluticasone propionate or mometasone furoate.
Study: NCT06527781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT06238154
Drug: Flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The efficacy of two different forms and amounts of active ingredient (100mg tablet vs 25% oral spray) on postoperative pain of different flurbiprofen
Study: NCT06252727
Drug: Aminolevulinic Acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01579890
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac topical lotion
Study: NCT05236608
Drug: ADG106
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an intravenous infusion over 90 minutes.
Study: NCT04078555
Drug: ENERGI-F703 GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first.~The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size.
Study: NCT04078555
Drug: ENERGI-F703 GEL matched vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first.~The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size.
Study: NCT05074394
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluent solution
Study: NCT05703204
Drug: QLF32101
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose is given weekly and observed for 28 days(DLT observation period).Single agent treatment.
Study: NCT05975645
Drug: TQB2618 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2618 injection is an inhibitor of T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3).
Study: NCT05104749
Drug: Homeopathic Medication
Normalized name: homeopathic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic medicines are prepared according to standardized methods as specified by the Homeopathic Pharmacopoeia of the United States (HPUS), which was mandated by Congress to regulate the manufacture of homeopathic medicines as part of the Food, Drug, and Cosmetics Act of 1939. All homeopathic medicines prescribed in this study must be found in the HPUS. For a complete list of homeopathic medicines, contact the researchers.
Study: NCT05001750
Drug: long term prophylactic antibiotics (Nafcillin or Doxycycline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRIs in patients who also receive a pre-procedural dose of antibiotics with continued dosing of antibiotics for the duration of the external ventricular drain IRB NUMBER: 2021-12680 IRB APPROVAL DATE: 06/14/2021 NOABX in EVD Study 3 (EVD).
Study: NCT05649878
Drug: Evaluation of bioavailability of methylprednisolone succinate administered intravenously
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioavailability of methylprednisolone in healthy subjects of both genders, when administered intravenously. The nominal doses were similar, volunteers were randomly assigned to receive a single dose of MEP by IV bolus of 1.5 mL. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
Study: NCT05649878
Drug: Evaluation of bioavailability of methylprednisolone succinate administered intranasally
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioavailability of methylprednisolone in healthy subjects of both genders, when administered intranasally. Volunteers were randomly assigned to receive a single dose of MEP intranasally by using a Mucosal Atomization Device (MAD Nasal). allowing direct pharmacokinetic comparison without dose normalization. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
Study: NCT05309902
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soticlestat placebo-matching tablet.
Study: NCT05309902
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin placebo-matching capsule.
Study: NCT06227897
Drug: Aumolertinib
Normalized name: aumolertinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aumolertinib 110 mg per day orally for 3 years.
Study: NCT05976802
Drug: Matching placebo rectal foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day for 2 weeks, then once a day for 4 weeks
Study: NCT05565391
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care
Study: NCT06506292
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oxaliplatin: 130 mg/m2,iv,d1; capecitabine: 1000 mg/m2,po,pid,d1-d14
Study: NCT06584240
Drug: Sequence 1
Normalized name: Antihemophilic Factor (Recombinant) Porcine Sequence 1 U Intravenous Powder for Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment, intramuscularly injected. The total injection 100-150U.
Study: NCT06584240
Drug: Sequence 5
Normalized name: antihemophilic factor VIII, recombinant porcine sequence 500 (+/-) unit range INTRAVEN VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment, intramuscularly injected.
Study: NCT04678830
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos
Study: NCT04789915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo add on to aripiprazole
Study: NCT04994743
Drug: CORT113176
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT113176 lipid capsule formulation for oral administration
Study: NCT04994743
Drug: Placebo matching CORT113176
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching CORT113176 lipid capsule formulation for oral administration
Study: NCT04865419
Drug: AZD0466
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0466 powder for concentrate for solution for infusion will be administered by IV infusion.
Study: NCT05102266
Drug: BR1016D
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
Study: NCT05073718
Drug: Low-dose acetylsalicylic acid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In case of being positive for SARS-CoV-2 PCR or antigen test, she will be randomised 1:1 to receive daily LDASA (125 mg) or placebo, up to 36 weeks of pregnancy.
Study: NCT05073718
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06315400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule/day for 5 days
Study: NCT04954040
Drug: Hydroxychloroquine Pill + Azithromycin Pill
Normalized name: hydroxychloroquine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine. 1st day 200mg 2-0-2; 2nd to 5th day 200mg 1-0-1 Azithromycin.~1st day 500m 0-1-0, 2nd to 5th day 250mg 0-1-0
Study: NCT04954040
Drug: SOC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen or Metamizole. Antitussives if needed.
Study: NCT06631976
Drug: 1ml of Depo-Medrol® injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml of methylprednisolone acetate (40mg/ml) injection into subacromial bursa.
Study: NCT06631976
Drug: Tropocells® PRP injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropocells® PRP injection. Patients will have an 11ml venous blood sample taken. After centrifugation, the obtained preparation will be administered to the patients intratendinously.
Study: NCT06629051
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Looks the same as berberine
Study: NCT04601467
Drug: AZD5718
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of AZD5718 (tablet) once daily for 12 months
Study: NCT04601467
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of matching placebo (tablet) once daily for 12 months
Study: NCT05230901
Drug: Spironolactone 25mg
Normalized name: SPIRONOLACTONE 25MG TAB
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with CMR-derived ECV% levels ≥25.9% in Arm Spironolactone will receive spironolactone 25 mg/d in addition to standard of care medication .
Study: NCT04731051
Drug: standard of care (SOC) for COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) for COVID-19
Study: NCT05796440
Drug: LUM-201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily
Study: NCT05276817
Drug: HP
Normalized name: HPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP solution will be inserted to the bottom of the periodontal pocket using a disposable side port needle applicator. The solution will be in the pocket for 30 seconds, and then removed using sterile gauze and water spray.
Study: NCT04709796
Drug: Conventional Transfer
Normalized name: SET,TRANSFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control arm is the conventional embryo transfer without Embryo glue medium
Study: NCT05077280
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opdualag (nivolumab 480mg and relatlimab 160mg) will be given every 4 weeks for two years
Study: NCT06121830
Drug: DWP14012 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 20mg, tablet, orally, once daily for up to 4 weeks
Study: NCT06121830
Drug: DWP14012 40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 40mg, tablet, orally, once daily for up to 4 weeks
Study: NCT06121830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, tablet, orally, once daily for up to 4 weeks
Study: NCT06310616
Drug: VH4524184
Approvals — FDA: no, EMA: no, PMDA: no
Description: VH4524184 will be administered.
Study: NCT05193604
Drug: TQB2858 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2858 injection is a programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β bispecific antibody.
Study: NCT04970654
Drug: Norditropin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norditropin® (0.034 mg/kg/day) will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.
Study: NCT05721170
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigation on beta-blockers in TAVI and brief post-TAVI period.
Study: NCT05289986
Drug: DELSTRIGO 100Mg-300Mg-300Mg Tablet
Normalized name: DELSTRIGO 100mg-300mg-300mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delstrigo (300 mg of tenofovir disoproxil fumarate equivalent to 245 mg of tenofovir disoproxil, 300 mg of lamivudine and 100 mg of doravirine~- TDF/3TC/DOR)
Study: NCT04246762
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, 100 mg, oral
Study: NCT05022147
Drug: OFF Dopaminergic Medication
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: All six device interventions will be performed in medication OFF state
Study: NCT05022147
Drug: ON Dopaminergic Medication
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: All six device interventions will be performed in medication ON state
Study: NCT03833024
Drug: Micronized Purified Flavonoid Fraction
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: After randomization (1:1 with stratification by centre) patients will receive 1000 mg of oral MPFF (Venixxa, one 500mg tablet BID) for 6 months, in addition to their usual PTS and DVT treatment
Study: NCT03833024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After randomization (1:1 with stratification by centre) patients will receive an oral placebo (one tablet BID) for 6 months, in addition to their usual PTS and DVT treatment
Study: NCT05826951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03692312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo formulation
Study: NCT04713670
Drug: (E) BQ-V14
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vonoprazan(vocinti)-based bismuth quadruple therapy for 14 days (BQ-V14)
Study: NCT04713670
Drug: (G) BQ-L14
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lansoprazole(takepron)-based bismuth quadruple therapy for 14 days (BQ-L14)
Study: NCT05921435
Drug: CKD-341, D958
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 1tablet under fasting condition
Study: NCT06109831
Drug: SHR-1918 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1918 placebo
Study: NCT05315024
Drug: Fluarix Tetra
Normalized name: Fluarix 2024-2025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluarix Tetra
Study: NCT04964479
Drug: TQB2450 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200mg injection once every 3 week
Study: NCT04964479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule once daily
Study: NCT05561023
Drug: Hawthorn red pigment
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients with refractory cancer pain who meet the enrollment conditions, on the basis of the clinician's normal adjustment of the analgesic regimen (the initial adjustment is the first day), the dose ramp up study of Hawthorn red pigment was started on the third day. The Hawthorn red dose group includes 10 tablets → 15 tablets → 20 tablets / time, orally, twice a day.~3 + 3 dose escalation scheme
Study: NCT05677282
Drug: Azithromycin 500 MG
Normalized name: azithromycin 500 MG
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 500 mg as a single dose administered orally.
Study: NCT03137966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.